ChitogenX Inc. CHNXF
0.01 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0011 Day range 0.0013
0.0011 52-week range 0.00755
- YTD
- 0.00%
- 1 year
- +586.36%
- Market cap
- 627.63K
- EPS (ttm)
- -0.01
- YTD return
- 0.00%
- 1-year return
- +586.36%
- Volume
- 50.00K
- Open
- 0.0013
- Previous close
- 0.00755
- Day's range
- 0.0011 – 0.0013
- 52-week range
- 0.0011 – 0.00755
2Y +0.0024 (+45.19%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 7, 2025 | Oct 1, 2024 | 0.00 | -0.01 | — | — |
| Sep 27, 2024 | Jul 1, 2024 | 0.00 | 0.00 | — | — |
| Jul 2, 2024 | Apr 1, 2024 | 0.00 | 0.00 | — | — |
| May 27, 2024 | Jan 1, 2024 | 0.00 | -0.01 | — | — |
| Jan 2, 2024 | Oct 1, 2023 | -0.01 | -0.01 | 0.00 | 0.00% |
| Sep 29, 2023 | Jul 1, 2023 | -0.02 | -0.01 | +0.01 | +50.00% |
News
ChitogenX ends 3Q with improved financial outlook; key milestones achieved 
ChitogenX demonstrates ORTHO-R efficacy and osteoarthritis protection in large animal meniscal repair study 
ChitogenX targets multi-billion dollar burn and skin repair market 
CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM 
ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform 
ChitogenX receives notice of allowance for key patent in the US and Canada 
ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial 
ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial 
ChitogenX pursuing new strategic development partnerships 
ChitogenX highlights milestones achieved in fiscal year
Your note
Sign in to keep a note on CHNXF — it syncs with the Stock Master app.